Molecular Diagnosis and Risk Stratification of Sepsis (MARS) Consortium

At a Glance
  • Status: Active Consortium
  • Year Launched: 2010
  • Initiating Organization: Center for Translational Molecular Medicine (CTMM)
  • Initiator Type: Government
  • Rare disease
  • Disease focus:
  • Location: Europe


The Molecular Diagnosis and Risk Stratification of Sepsis (MARS) consortium aims to generate tools that provide rapid and accurate information about an individual patient suffering from sepsis, including which microorganism is responsible for the infection and the severity and stage of the immune response. These tools should be easy to use, be at or close to the patient’s bedside, and provide rapid information to the physician about how to treat each individual patient in the best way.


The program is organized into the following four Work Packages (WPs):

Consortium History

2010: Consortium started
2013: Data collection completed
2015: Consortium scheduled to complete


In response to the first call for project proposals in 2007, the Center for Translational Molecular Medicine (CTMM) announced on April 1, 2008, that nine first-call projects would receive research funding amounting to a total of €150 million. On March 10, 2009, it announced that eight new project proposals, submitted in the fall of 2008 in response to the second call for proposals, would receive funding amounting to a total of almost €100 million.
All Dutch university medical centers, plus several universities, a broad spectrum of small and medium-sized enterprises, major industry leaders including Philips and DSM Biomedical Materials, and the Dutch government are involved.
Funding is provided by the Dutch government, industry, and academia. Research is focused firmly on the translational aspects of molecular medicine so that results can be applied as quickly as possible to actual patient care.
MARS is one of the projects from the second call, with a project budget of €14 million, of which 50 percent is contributed by the Dutch government.

Other website

Points of Contact

Principal investigator: Tom van der Poll (Academic Medical Center, Amsterdam)
CTMM program manager: Henny Bruinewoud

Sponsors & Partners

Academisch Medisch Centrum (AMC) Amsterdam


Check-Points Health BV

Immunetrics Inc.


Microbiome Ltd.

Philips Electronics Nederland BV

Universitair Medisch Centrum St Radboud, Nijmegen

Universitair Medisch Centrum Utrecht (UMCU)

Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.